PEPID Pulse
  • Blog
  • Alerts
  • Press
  • pepid.com
Select Page
First P13K inhibitor for Breast Cancer Gets FDA Approved

First P13K inhibitor for Breast Cancer Gets FDA Approved

by PEPID Newsroom | May 24, 2019 | Alerts

Pigray (alpelisib) tablets have been FDA approved to treat breast cancer in combination with FDA-approved endocrine therapy fulvestrant. Pigray is approved for postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2...

Recent Posts

  • The Summer Injury Spike: Common ER Visits and How to Prevent Them
  • Men’s Health Month – Closing Gaps in Prevention and Early Detection
  • Beyond the Beach – Occupational Skin Cancer Risks in Outdoor Workers
  • Tackling Antimicrobial Resistance: How to fight back against the rise in tough cases
  • The ‘Forever Chemicals’ Crisis: What Healthcare Providers Need to Know About PFAS

Categories

  • Alerts
  • Emergency Medicine
  • Featured Posts
  • Nursing
  • Pharmacy
  • Press & Media
  • Primary Care
  • Uncategorized
PEPID, LLC. All rights reserved